8-K: Tyra Biosciences Advances Clinical Pipeline, Reports Q2 Results

Tyra Biosciences reports Q2 2025 financial results and significant progress across its clinical-stage precision medicine pipeline, including dosing the first patient in a Phase 2 bladder cancer study.

Summary

• Tyra Biosciences reported cash, cash equivalents, and marketable securities of $296.3 million as of June 30, 2025, providing a runway through at least 2027.
• The company dosed the first patient in SURF302, a Phase 2 study evaluating dabogratinib for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
• The Phase 2 BEACH301 study for achondroplasia with dabogratinib is advancing and is now enrolling a safety sentinel cohort in children aged 5 to 10.
• Preclinical results for dabogratinib presented at ENDO 2025 showed significant improvement in skull and foramen magnum size/shape and increased bone growth in FGFR3-driven models, supporting broader development in skeletal dysplasias.
• Patient dosing is ongoing in the Phase 1 SURF431 study for TYRA-430 in advanced hepatocellular carcinoma (HCC) and other solid tumors.
• The Phase 1 SURF201 study for TYRA-200 continues to enroll and dose adults with intrahepatic cholangiocarcinoma and other advanced solid tumors.
• Research and Development (R&D) expenses increased to $24.3 million for Q2 2025, up from $18.0 million in Q2 2024, driven by clinical trial activities and personnel costs.
• General and Administrative (G&A) expenses increased to $7.1 million for Q2 2025, up from $5.5 million in Q2 2024, primarily due to higher personnel-related costs.
• Net loss for the second quarter was $28.1 million, compared to $18.7 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant clinical progress across multiple programs, strong cash reserves providing a long runway, and positive preclinical data. The increased net loss and expenses are expected for a company in this stage of development and do not detract from the overall positive outlook on operational execution.

Positives

• Strong cash position of $296.3 million as of June 30, 2025, providing a projected cash runway through at least 2027.
• Dosed the first patient in the Phase 2 SURF302 study for IR NMIBC, marking significant clinical advancement for dabogratinib.
• Advanced the Phase 2 BEACH301 study for achondroplasia, with enrollment ongoing for a safety sentinel cohort.
• Positive preclinical data for dabogratinib presented at ENDO 2025 supports expanding its development into skeletal dysplasias beyond achondroplasia.
• Multiple other pipeline programs (TYRA-430 in SURF431 and TYRA-200 in SURF201) are actively enrolling and dosing patients.
• Clear upcoming clinical milestones, including dosing the first child in BEACH301 by 3Q 2025 and topline data from SURF302 by 1H 2026.

Negatives

• Increased net loss to $28.1 million in Q2 2025, up from $18.7 million in Q2 2024.
• Higher Research and Development (R&D) expenses of $24.3 million in Q2 2025, compared to $18.0 million in Q2 2024.
• Increased General and Administrative (G&A) expenses of $7.1 million in Q2 2025, compared to $5.5 million in Q2 2024.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and may materially change.
• Proof-of-concept results may fail to lead to successful subsequent development of dabogratinib.
• Later developments with the FDA may be inconsistent with prior feedback.
• The SNP platform is novel and unproven and may not lead to successful product candidates or approved products.
• Potential delays in the commencement, recruitment, enrollment, data readouts, and completion of preclinical studies and clinical trials.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• Dependence on third parties for manufacturing, research, and preclinical testing.
• Limited resources may be expended on a product candidate or indication that fails to capitalize on greater potential.
• Acceptance by the FDA or comparable foreign regulatory authorities of INDs or similar regulatory submissions is not guaranteed.
• An accelerated development or approval pathway may not be available or lead to a faster development process.
• Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization.
• Programs and prospects may be negatively impacted by developments relating to competitors.
• Unfavorable results from preclinical studies.
• Regulatory developments in the United States and foreign countries.
• Ability to obtain and maintain intellectual property protection for product candidates and proprietary technologies.
• Capital resources may be used sooner than expected.
• Unstable market and economic conditions and changes in healthcare legislation, tariffs, and trade policies may adversely affect the business and financial condition.

Future Outlook

The company expects to continue advancing its pipeline, including dabogratinib for bladder cancer and skeletal dysplasia, and other precision medicines. It anticipates delivering meaningful Phase 2 readouts for SURF302 and BEACH301. The SNP platform is expected to continue developing therapies. The current cash, cash equivalents, and marketable securities are projected to fund operations through at least 2027.

Management Comments

• "We see significant opportunity to transform the treatment of bladder cancer and skeletal dysplasia by precisely targeting FGFR3."
• "With BEACH301 open for enrollment and SURF302 advancing in intermediate-risk non-muscle invasive bladder cancer, we're building a franchise with dabogratinib around the power of FGFR3 selectivity and sensitivity."
• "Backed by a strong balance sheet, we're well positioned to deliver meaningful Phase 2 readouts in SURF302 and BEACH301."

Industry Context

Tyra Biosciences operates in the highly competitive clinical-stage biotechnology sector, specifically focusing on Fibroblast Growth Factor Receptor (FGFR) biology. The development of targeted therapies for FGFR-driven cancers and genetically defined conditions like achondroplasia aligns with broader industry trends towards precision medicine. The company's strategy to develop FGFR3-selective inhibitors aims to address unmet needs by potentially offering improved safety profiles compared to less selective FGFR inhibitors, which have faced challenges with off-target toxicities. Advancing multiple clinical programs, particularly in bladder cancer and achondroplasia, positions Tyra within a niche but growing market for targeted oncology and rare disease treatments.

Comparison to Industry Standards

• The company's cash runway through at least 2027, with $296.3 million in cash, cash equivalents, and marketable securities, is robust for a clinical-stage biotech, providing significant operational flexibility compared to many peers who often face shorter cash horizons.
• The advancement of dabogratinib into Phase 2 studies for IR NMIBC (SURF302) and achondroplasia (BEACH301) demonstrates progress in line with typical clinical development timelines for novel targeted therapies, though specific comparable trial timelines are not detailed in the filing.
• The preclinical data for dabogratinib showing improved skull and foramen magnum size/shape in Fgfr3Y367C/+ mice and increased bone growth in FGFR3-driven models is a positive indicator for its potential in skeletal dysplasias, a field where companies like BioMarin Pharmaceutical (with Voxzogo for achondroplasia) are established, suggesting a competitive landscape for Tyra's BEACH301 program.
• The focus on FGFR3 selectivity for dabogratinib aims to differentiate it from broader FGFR inhibitors, such as those developed by companies like Incyte (Pemigatinib) or Janssen (Balversa), which target multiple FGFR subtypes and may have different toxicity profiles. Tyra's approach seeks to minimize off-target effects, a key challenge in FGFR inhibition.

Stakeholder Impact

• **Shareholders:** Positive impact from strong cash runway, active clinical development, and upcoming milestones, which could drive future value. Increased burn rate is expected but managed by current cash.
• **Patients:** Potential for new treatment options for intermediate-risk non-muscle invasive bladder cancer, achondroplasia, advanced hepatocellular carcinoma, and intrahepatic cholangiocarcinoma if clinical trials are successful.
• **Employees:** Continued employment and potential growth opportunities as clinical programs advance and the company expands its research and development efforts.
• **Creditors:** Stable financial position with significant cash reserves reduces immediate credit risk.
• **Suppliers/Partners:** Continued engagement and potential for increased business as clinical trials and manufacturing activities progress.

Next Steps

• Dose first child with achondroplasia in the BEACH301 study (expected 3Q 2025).
• Release topline initial three-month complete response data from the SURF302 study (expected 1H 2026).
• Continue patient dosing in the Phase 1 SURF431 study for TYRA-430.
• Continue enrollment and dosing in the Phase 1 SURF201 study for TYRA-200.
• Continue evaluation of dabogratinib in Part B of SURF301 for potential future Phase 2 studies in mUC.

Key Dates

Recommendation

Tyra Biosciences demonstrates solid execution on its clinical development pipeline, with multiple programs advancing and clear upcoming milestones. The strong cash position provides a substantial runway, mitigating near-term funding concerns. While the increased net loss is expected for a clinical-stage biotech, the company's progress in addressing significant unmet medical needs in FGFR biology is promising. The stock is a 'hold' as it continues to execute on its clinical strategy, with future catalysts tied to clinical data readouts. Investors should monitor these upcoming data releases for potential re-evaluation.

Keywords

Tyra Biosciences, TYRA, Biotechnology, Clinical-stage, Precision Medicine, FGFR, Dabogratinib, TYRA-300, Bladder Cancer, NMIBC, Achondroplasia, Skeletal Dysplasia, Oncology, Rare Disease, Clinical Trials, SURF302, BEACH301, SURF301, TYRA-430, HCC, TYRA-200, Cholangiocarcinoma, SNP Platform, Financial Results, R&D Expenses, Cash Runway